![AbbVie](https://www.pharmacompass.com/image/flap/abbvie-corp-adgif-27965.gif)
![AbbVie](https://www.pharmacompass.com/image/flap/abbvie-corp-ad-w33-mob-headergif-39012.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Joint Venture Company is vested with the exclusive right to develop, register, distribute and commercialize Promethera®'s therapeutic products (cell therapies and antibodies developed by Promethera® Group) in China and Southeast Asia.
Lead Product(s): HepaStem
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: HepaStem
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Aceso Life Science Holding
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 17, 2020
Details:
The trial is open for recruitment and aims to include 363 patients with ACLF at 110 study sites across 22 countries in Europe.
Lead Product(s): HepaStem
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020